Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 67, Issue 1, 2002, Pages 45-49

  Matsukawa, Y ^a   Saito, O ^a   Aoki, M ^a   Abe, M ^b   Nishinarita, S ^a   Sawada, S ^a   Horie, T ^a   Naruse, S ^c   Hiranuma, M ^d  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Abe Clinic   (Japan)

^c Kamifukuoka Kyodoh Clinic   (Japan)

^d Akiru Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; PROSTACYCLIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FACE PAIN; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART OUTPUT; HOT FLUSH; HUMAN; LONG TERM EXPOSURE; LUNG CAPACITY; LUNG DIFFUSION; LUNG FUNCTION; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; REFERENCE VALUE; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

EID: 0036661395     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2002.0380     Document Type: Article

References (34)

1. Jimenez S. A., Sigal S. H. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991; 18: 1496-1503.
2. Akesson A., Scheja A., Lundin A., Wollheim F. A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthrit Rheum 1994; 37: 729-735.
3. Silver R. M., Warrrick J. H., Kinsella M. B., Staudt L. S., Baumann M. H., Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-844.
4. Steen V. D., Lanz Jr J. K., Conte C., Owens G. R., Medsger Jr T. A. Therapy for severe interstitial lung disease in systemic sclerosis. Arthrit Rheum 1994; 37: 1290-1296.
5. White B., Moore W. C., Wigley F. M., Xiao H. Q., Wise R. A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-954.
6. Uematsu T., Murata T., Tanaka Y., Osada E., Nishio S. Antithrombotic effect of TRK-100, a novel, stable PGI2 analogue. Jpn J Pharmacol 1987; 43: 81-90.
7. Yoshitomi Y., Kojima S., Kuramochi A. Long-term effect of a new oral prostacyclin analogue, beraprost sodium, in isolated pulmonary artery stenosis in the adult. J Intern Med 1999; 246: 227-230.
8. Vayssairat M. Preventive effect of an oral prostacyclin analogue, beraprost sodium, on digital necrosis in systemic sclerosis. French Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999; 26: 2173-2179.
9. Yagi T., Oishi M., Sadamori H., Matsuno T., Tanaka N. Successfully treated renal artery stenosis using an oral PGI2 derivative, beraprost, in cadveric kidney transplantation. Nephron 2000; 85: 188-189.
10. Lievre M., Morand S., Besse B., Fiessinger J. N., Boissel J. P. Oral beraprost sodium, a prostaglandin 12 analogue, for intermittent claudication: a double-blind, multicenter controlled trial. Beraprost et Claudication Intermittent (BERCI) Research Group. Circulation 2000; 102: 426-431.
11. Mata J., Gomez-Sanchez M. A., Aranzana M., Gomez-Reino J. J. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthrit Rheum 1994; 37: 1528-1533.
12. Barst R. J., Rubin L. J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
13. Humbert M., Sanchez O., Fartoukh M., Jagot J. L., Sitbon O., Simonneau G. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (Prostacyclin). Chest 1998; 114: 80S-82S.
14. McLaughlin V. V., Genthner D. E., Panella M. M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
15. Menon N., McAlpine L., Peacock A. J., Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthrit Rheum 1998; 41: 466-469.
16. Nagaya N., Uematsu M., Okano Y., et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188-1192.
17. Badesch D. B., Tapson V. F., McGoon M. D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. Ann Intern Med 2000; 132: 425-434.
18. Olschewski H., Ghofrani A., Schmehl T., et al. Inhaled iloprost to treat severe pulmonary hypertension. Ann Intern Med 2000; 132: 435-443.
19. Hoeper M. M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-1870.
20. Subcommitee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthrit Rheum 1980; 23: 581-590.
21. Kato S., Kishiro I., Machida M., Fuse D., Yoshida T., Kaneko N. Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. J Int Med Res 2000; 28: 258-268.
22. Scorza R., Caronni M., Mascagni B., et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp heumatol 2001; 19: 503-508.
23. Yagi T., Oishi M., Matsuda H., et al. Improvement of myointimal hyperplasia in a patient with transplant renal artery stenosis by oral PGI2. Transplant Proc 1998; 30: 3043-3044.
24. Demolis J. L., Robert A., Mouren M., Funck-Brentano C., Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Card Vasc Pharmacol 1993; 22: 711-716.
25. Friedman R., Mears J. G., Barst R. J., Mears J. G., Barst R. J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784.
26. Yang L., Yatomi Y., Satoh K., Ozaki Y. Inhibitory effects of beraprost on platelet aggregation: comparative study utilizing two methods of aggregometry. Thromb Res 1999; 94: 25-32.
27. Dowd P. M., Kovacs I. B., Bland C. J. H., Kirby J. D. T. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Lancet 1981; 283(1): 350-351.
28. Belch J. J. F., McLaren M., Anderson J., et al. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostagl Leukotr Med 1985; 17: 1-9.
29. Kouchi Y., Esato K., O-Hara M., Zempo N. Effect of prostaglandin I2 analogue TRK-100 on the suppression of intimal fibrous proliferation. J Vasc Surg 1992; 16: 232-238.
30. Koh E., Morimoto S., Jiang B., et al. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 1993; 20: 242-252.
31. Sakai A., Yajima M., Nishio S. Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci 1990; 47: 711-719.
32. Kainou M., Nishio S., Nakadate T. Cytoprotective action of beraprost sodium against peroxide-induced damage in vascular endothelial cells. Pharmacology 1992; 45: 61-70.
33. Ichida F., Uese K., Hamamichi Y., et al. Chronic effect of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension. Acta Paediatr Japan 1998; 40: 14-19.
34. Reilly I. A. G., Roy L., Fitzgerald G. A. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. BMJ 1986; 292: 1037-1039.